-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 4, 2025

Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

Author(s)Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA , Melody Chang, RPh, MBA, BCOP, Nicholas Bouchard, PharmD

Experts discuss how they balance safety, efficacy, and overall patient prognosis when selecting third-line treatments for metastatic colorectal cancer (mCRC) and explore how the toxicity profiles of fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab differ, informing treatment decisions.

Episodes in this series

EP. 1 Treatment Options in mCRC: A Clinical Overview

EP. 1 Treatment Options in mCRC: A Clinical Overview

EP. 2 Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

EP. 2 Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

EP. 3 Quality of Life and Patient Outcomes in mCRC Treatment

EP. 3 Quality of Life and Patient Outcomes in mCRC Treatment

EP. 4 Optimizing Treatment Sequencing in Advanced Colorectal Cancer

EP. 4 Optimizing Treatment Sequencing in Advanced Colorectal Cancer

EP. 5 The Patient Journey: Mapping the Pharmacist’s Role in mCRC Management

EP. 5 The Patient Journey: Mapping the Pharmacist’s Role in mCRC Management

EP. 6 Evolution of Oncology Pharmacy Practice in mCRC

EP. 6 Evolution of Oncology Pharmacy Practice in mCRC

EP. 7 Pharmacist-Led Strategies for Adverse Event Management in mCRC

EP. 7 Pharmacist-Led Strategies for Adverse Event Management in mCRC

EP. 8 Navigating Cost Considerations in Treatment Selection of mCRC Agents

EP. 8 Navigating Cost Considerations in Treatment Selection of mCRC Agents

EP. 9 Best Practices for Overcoming mCRC Prior Authorization Barriers

EP. 9 Best Practices for Overcoming mCRC Prior Authorization Barriers

EP. 10 Building Better Collaboration: Reducing Care Delays in Managing mCRC

EP. 10 Building Better Collaboration: Reducing Care Delays in Managing mCRC

Video content above is prompted by the following:

When selecting third-line treatments for mCRC, how do you balance safety, efficacy, and overall patient prognosis?
How do the toxicity profiles of fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab differ, and how can these differences inform treatment decisions?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Emerging Data and the Future Treatment Landscape in Extrapulmonary Neuroendocrine Carcinoma: Novel Therapies, Algorithms, and Combination Strategies

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 13th 2026

Unmet Needs and Emerging Mechanisms of Action in Extrapulmonary Neuroendocrine Carcinoma: The Path Toward Better Therapies

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 13th 2026

Risk Stratification and Weight Loss as Therapy: A Hepatologist's Framework for Managing MASH Progression

ByNadege Gunn, MD

July 10th 2026

Screening MASH Upstream: Building a Practical, Scalable Algorithm for the Real World

ByNadege Gunn, MD

July 10th 2026

Experts featured in this series.

Fixing the Mental Health System: Burnout, Advocacy, and the Case for Team-Based Care

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: July 7th 2026 | Updated: June 16th 2026

Trending on AJMC

NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues

Female Newborns More Likely to Miss Vitamin K Prophylaxis, Hepatitis B Birth Dose

FDA Approved At-Home SC Lecanemab Initiation Dose for Early Alzheimer Disease

Medicaid Fraud Crackdown Intensifies, But Is It Solving the Right Problem?

Provider Trust, Social Media Use Can Shape Vaccine Myth Belief